AstraZeneca and its stilted R&D division aren't scheduled to move to Cambridge, U.K., until 2016, but the drugmaker can't wait to settle in at what it calls "one of the world's preeminent biosciences hotspots," planning to send an advance team of scientists to plant some collaborative seeds.
AstraZeneca is in the midst of transferring its global R&D base to a $500 million campus in Cambridge, U.K., shouldering up with the famed institution in hopes of replicating other companies' success in biotech hubs and jump-starting its pipeline.
France's Ipsen is the latest drug developer with eyes on Cambridge, MA's booming biotech hub, plotting to move its U.S. R&D activities to Kendall Square.
Walk into Biogen Idec's new complex in Cambridge, MA, and you might notice something's missing--there are no cubicles or private offices in the 6-story, 190,000-square-foot office, reports The Boston Globe.
Over the next three years the pharma company plans to build a $500 million complex on its new campus that will house its U.K. operations for biologics and small molecule research as well as the corporate staff now operating in London.
And Pfizer plans to relocate most of its 530 employees from its operations in the Alewife section of Cambridge closer to where about 400 of the pharma giant's employees are working in Kendall Square, The Boston Globe reported.
Today's Telegraph gives AstraZeneca a rousing hurrah today in a lengthy piece, noting that its plans to build a new $500 million facility in Cambridge, U.K., has the potential to fast-track the area's emergence as a major global biotech hub.
J&J is about to make a big entrance in the Boston/Cambridge hub. The Boston Business Journal reports today that the pharma giant has taken a lease on new digs in Kendall Square for one of its four global innovation centers--putting it right in the heart of one of the busiest biotech regions in the world.
Like pioneers rushing for gold, biotech and pharma outfits have swept into Cambridge, MA, and dismissed the hefty property costs in search of talent and technology that could lead to lucrative new drugs.
Plans call for the Massachusetts Accelerator for Biomanufacturing to attract a host of startups and companies that will hopefully put the small city on the biotech map.